Cargando…

Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis

Lung cancer is the leading cause of cancer-related death worldwide and has a high incidence rate. N-Acetyltransferase 2 (NAT2) is a polymorphic xenobiotic enzyme, which can catalyze N-acetylation and O-acetylation of various carcinogens such as aromatic, heterocyclic amines and hydrazines. At presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ke, Xu, Aiqun, Xia, Wanli, Li, Pulin, Zhang, Binbin, Jiang, Huihui, Zhou, Sijing, Wang, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991837/
https://www.ncbi.nlm.nih.gov/pubmed/33777732
http://dx.doi.org/10.3389/fonc.2021.567762
_version_ 1783669252456185856
author Zhu, Ke
Xu, Aiqun
Xia, Wanli
Li, Pulin
Zhang, Binbin
Jiang, Huihui
Zhou, Sijing
Wang, Ran
author_facet Zhu, Ke
Xu, Aiqun
Xia, Wanli
Li, Pulin
Zhang, Binbin
Jiang, Huihui
Zhou, Sijing
Wang, Ran
author_sort Zhu, Ke
collection PubMed
description Lung cancer is the leading cause of cancer-related death worldwide and has a high incidence rate. N-Acetyltransferase 2 (NAT2) is a polymorphic xenobiotic enzyme, which can catalyze N-acetylation and O-acetylation of various carcinogens such as aromatic, heterocyclic amines and hydrazines. At present, many studies have explored the effects of NAT2 polymorphism on lung cancer, but we found inconsistent results. We researched 18 published studies, involving 4,016 patients and 5,469 controls, to more accurately assess the effects of NAT2 polymorphism on lung cancer risk and to investigate whether smoking is associated. We used STATA software to analyze the extracted data and used STATA for subgroup analysis, sensitivity analysis, and to perform publication bias tests. To determine the correlation, we used the crude odds ratio (ORs) with 95% confidence interval (CIs). Our study was prospectively registered in PROSPERO (CRD42020159737). The odds ratio was 1.53 (95% CI: 1.21–1.95, I² = 45.2%, P=0.104) for the NAT2 slow + intermediate phenotype versus rapid phenotype. The results suggested that people with NAT2 non-rapid (slow + intermediate) phenotype have a significantly increased risk of lung cancer. In addition, NAT2 rapid phenotype was significantly associated with reduced risk of lung cancer, compared with slow phenotype or intermediate phenotype (slow phenotype vs. rapid phenotype: OR: 1.61, 95% CI: 1.07–2.42, I²= 50%, P= 0.075; intermediate phenotype vs. rapid phenotype: OR: 1.47, 95% CI: 1.15–1.88, I²= 40.3%, P= 0.137).
format Online
Article
Text
id pubmed-7991837
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79918372021-03-26 Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis Zhu, Ke Xu, Aiqun Xia, Wanli Li, Pulin Zhang, Binbin Jiang, Huihui Zhou, Sijing Wang, Ran Front Oncol Oncology Lung cancer is the leading cause of cancer-related death worldwide and has a high incidence rate. N-Acetyltransferase 2 (NAT2) is a polymorphic xenobiotic enzyme, which can catalyze N-acetylation and O-acetylation of various carcinogens such as aromatic, heterocyclic amines and hydrazines. At present, many studies have explored the effects of NAT2 polymorphism on lung cancer, but we found inconsistent results. We researched 18 published studies, involving 4,016 patients and 5,469 controls, to more accurately assess the effects of NAT2 polymorphism on lung cancer risk and to investigate whether smoking is associated. We used STATA software to analyze the extracted data and used STATA for subgroup analysis, sensitivity analysis, and to perform publication bias tests. To determine the correlation, we used the crude odds ratio (ORs) with 95% confidence interval (CIs). Our study was prospectively registered in PROSPERO (CRD42020159737). The odds ratio was 1.53 (95% CI: 1.21–1.95, I² = 45.2%, P=0.104) for the NAT2 slow + intermediate phenotype versus rapid phenotype. The results suggested that people with NAT2 non-rapid (slow + intermediate) phenotype have a significantly increased risk of lung cancer. In addition, NAT2 rapid phenotype was significantly associated with reduced risk of lung cancer, compared with slow phenotype or intermediate phenotype (slow phenotype vs. rapid phenotype: OR: 1.61, 95% CI: 1.07–2.42, I²= 50%, P= 0.075; intermediate phenotype vs. rapid phenotype: OR: 1.47, 95% CI: 1.15–1.88, I²= 40.3%, P= 0.137). Frontiers Media S.A. 2021-03-11 /pmc/articles/PMC7991837/ /pubmed/33777732 http://dx.doi.org/10.3389/fonc.2021.567762 Text en Copyright © 2021 Zhu, Xu, Xia, Li, Zhang, Jiang, Zhou and Wang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhu, Ke
Xu, Aiqun
Xia, Wanli
Li, Pulin
Zhang, Binbin
Jiang, Huihui
Zhou, Sijing
Wang, Ran
Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis
title Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis
title_full Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis
title_fullStr Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis
title_full_unstemmed Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis
title_short Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis
title_sort association between nat2 polymorphism and lung cancer risk: a systematic review and meta-analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991837/
https://www.ncbi.nlm.nih.gov/pubmed/33777732
http://dx.doi.org/10.3389/fonc.2021.567762
work_keys_str_mv AT zhuke associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis
AT xuaiqun associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis
AT xiawanli associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis
AT lipulin associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis
AT zhangbinbin associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis
AT jianghuihui associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis
AT zhousijing associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis
AT wangran associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis